1Strategies to support drug clinical research in older population in the United States and European UnionZHANG Yi-nan, Li Xin-chen, WU Ting-xi, ZHAO Zhi-gang1-52Definition of rare diseases in China and measurement of cumulative point prevalence based on Orphanet databaseGUO Qi-xiang, LIU Yun-peng, ZHU Jia-zhen, YANG Yue6-113Comparison of the accelerated marketing and registration system for innovative drugs in countries along"The Belt and Road"and its implicationsYUAN Fang-zhe, HAN Jia-jia, YANG Feng-hong, WANG Xi-rui, CHEN Yue-jiao, CHU Shu-zhen12-194A study on the dilemma and countermeasures of drug off-site inspection in ChinaZHANG Jie-ying, LI Jun, ZHAO Feng, FAN Rui-xue, ZHANG Miao-miao, MAO Ning-ying20-265Research status and countermeasure analysis on substitutes for rare and endangered Chinese medicinal materialsRUAN Yi-dan, ZHANG Ping-zhi, ZHANG Yong-qiang, YAO Ai-na, ZHANG Hui-zhong, XU Xiao-han, LI Shi-man, NI Jian, DONG Xiao-xu27-346Key considerations for the CMC research of antibody-drug conjugates during the investigational new drug stageDAI Yi-fei, XIE Yu-jia, YANG Jiao, CHEN Ai-ping, REN Feng, LI Qian, HE Wu35-427Clinical development and evaluation of human respiratory syncytial virus vaccinesCHEN Yan, WANG Hai-xue43-518Considerations for pharmaceutical studies of prophylactic self-amplifying RNA vaccinesYANG Dan, ZHAO Xin, HU Lin, ZHANG Dong, LI Min52-569Advance in study on classic prescription Taohechengqi decoctionZHANG Yong-qiang, NI Jian, CAI Meng-ru, KONG Jia-hui, LIAO Shi-lang, DU Yu-ji, RUAN Yi-dan, ZHU Rong-yue, FU Ting-ting, YIN Xing-bin, DONG Xiao-xu57-6510The development of pharmacotoxicological techniquesLIU Qian, LIU Zhi-wei, GU Ai-hua66-7211Synthesis and detection of potential genotoxic impurities in nebivolol hydrochlorideWANG Yi-xuan, HUANG Hai-wei, HU Xiao-wen, ZHANG Cai-yu, YU Li-ju, YUAN Song, CHEN Hua73-7912Process research on the formula granules of Cinnamomum migaoYUAN Hong-fei, XIAO Jin-chao, ZHOU Jia-hua, HUANG Yong, LI Yue-ting, CHI Ming-yan, ZHENG Lin80-8813Quantitative determination of fluoxetine hydrochloride in conventional solid oral formulations using 19F qNMR methodLI Zeng-xin, ZHOU Xiao-li, LIU Wan-hui, YIN Li-hui89-9314Optimization of the processing technology of Artemisiae extract by Box-Behnken response surface method and its quality controlWANG Yue, WANG Ya-qian, DING Yin, GOU Xiao-ling, HUANG Xue-mei, XIE Yu-chen, ZHANG Jing, FAN Gang94-10115Rapid health technology evaluation of trastuzumab deruxtecan in the treatment of advanced or metastatic breast cancerJIANG Yi, ZHANG Zhuo, LIU Qian-xin, ZHANG Zhi-qi, LIU Xiao, ZHOU Ying102-109